Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04720443 · ClinicalTrials.gov registry record · Phase 1
A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects
A Phase 1 study of Idiopathic Pulmonary Fibrosis, sponsored by The National Institutes of Pharmaceutical R&D Co. Ltd, China.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT04720443 is a Phase 1 study of Idiopathic Pulmonary Fibrosis that has completed, run by The National Institutes of Pharmaceutical R&D Co. Ltd, China. The registered enrollment target is 56 participants, below the 750-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04720443, a Phase 1 study of Idiopathic Pulmonary Fibrosis, has completed, sponsored by The National Institutes of Pharmaceutical R&D Co. Ltd, China.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being conducted to evaluate the safety and tolerability of single ascending and multiple ascending oral doses of NIP292 tablets administered following an overnight fast in healthy adult subjects.
Conditions Studied
Interventions
- DRUG NIP292 tablet
Study Locations (1)
California
- PAREXEL International - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2019-11-22 |
| Est. Completion | 2022-07-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04720443
The ClinicalTrials.gov registry entry for NCT04720443 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 750-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (93% lower). The listed sponsor is The National Institutes of Pharmaceutical R&D Co. Ltd, China, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which NIP292 tablet is the first listed.
NCT04720443 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04720443 about?
NCT04720443 is a clinical study titled "A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects". This study is being conducted to evaluate the safety and tolerability of single ascending and multiple ascending oral doses of NIP292 tablets administered following an overnight fast in healthy adult subjects.
What is the current status of trial NCT04720443?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2019-11-22. Estimated completion is 2022-07-14.
What conditions does trial NCT04720443 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.
What interventions are being tested in trial NCT04720443?
The interventions under investigation include: NIP292 tablet (DRUG).
Who is sponsoring clinical trial NCT04720443?
This trial is sponsored by The National Institutes of Pharmaceutical R&D Co. Ltd, China, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04720443 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose-Escalation Study of Artesunate Patients With IPF
RECRUITING · Phase 1
-
Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
RECRUITING · Phase 1
-
A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNS-3545 in Healthy Participants
RECRUITING · Phase 1
-
NAL ER IPF Respiratory Function and Safety Study
RECRUITING · Phase 1
-
Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 1
-
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.